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Morphometry of the hippocampal microvasculature in post-stroke and age-related dementias
Background: Optimal vascular function is vital for preven-
tion of dementia. We hypothesized that elderly post-stroke
survivors who preserve cognitive function show unper-
turbed cerebral microvasculature compared with those
who develop dementia. Methods: Using stereological
spherical probe software, we compared the length density
(Lv, cumulative vessel length per unit tissue volume) of
hippocampal microvessels in post mortem brain tissue from
post-stroke survivors, Alzheimer’s disease (AD), vascular
dementia (VaD) and normal ageing control subjects. We
also assessed microvessel diameters in the same subjects.
Microvessels were identified by markers of endothelial
cells (glucose transporter 1; GLUT1), basement mem-
brane (collagen IV; COL4) and smooth muscle cell α-actin
(SMA). Results: We found increased Lv of both GLUT1 and
COL4 immunostained microvessels (P < 0.05) in the
hippocampal CA1 region of post-stroke demented (PSD)
and AD cases compared with post-stroke nondemented
(PSND), control and VaD subjects. However, no changes
were apparent in the CA2 region. We also noted signifi-
cant increase in Lv in the entorhinal cortex of AD com-
pared with PSND and PSD subjects. The mean diameter of
microvessels was decreased in PSD, compared with PSND,
as well as in AD and VaD compared with controls. Cumu-
lative frequency analysis showed PSND subjects to have
significantly greater proportion of microvessels with
diameters, ranging from 7 to 12 μm. Conclusions: An
increase in microvascular Lv in AD and PSD suggests
either an increase in angiogenesis or the formation of
newer microvessel loops in response to cerebral
hypoperfusion. The decreased vessel diameters found
in AD and VaD suggests increased vasoconstriction in
dementia.
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Introduction
Previous epidemiological studies have shown that vascu-
lar disease plays a key role in the progression of dementia
[1, 2], inclusive of cardiovascular risk factors, such as
increased blood pressure [3], atrial fibrillation [4], diabe-
tes mellitus [5] and other vascular disease-related factors
[6]. Magnetic resonance imaging (MRI) studies using
arterial spin labelling, have shown a reduction in cer-
ebral blood flow (CBF) in the temporal lobe associated
with dementia in Alzheimer’s disease (AD) [7] and in
post-stroke survivors [8]. In these scenarios, the decrease
in CBF is thought to result from neurodegeneration,
whereby the cerebral microvasculature is modulated due
to lower demand for glucose and oxygen. However, an
alternative view has also been proposed, in which case
the decrease in CBF may be the cause or instigator of
neurodegeneration [9]. Consistent with this latter
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hypothesis, we recently proposed there is a vascular basis
for neuronal atrophy and likely neurodegeneration in
post-stroke demented (PSD) subjects without significant
AD pathology [10].
The role of the cerebral microvasculature in age-
related dementias continues to be unclear. Using different
methods of assessment, previous studies in dementia have
suggested microvessel density, is decreased in dementia,
especially in AD [11–13], whereas others claim it is
increased [14–16]. Some investigators have also demon-
strated narrowing of microvessels in the CA1 of the
hippocampus and entorhinal cortex (EC) of AD subjects
[14, 17]. Differences in the methods of analysis and brain
regions investigated may explain the variable results.
However, studies in AD have indicated that there is an
up-regulation or modulation of pro-angiogenic proteins
and vascular growth factors [18], which may increase the
density of the microvasculature [19–21]. Studies involv-
ing transgenic (Tg) mice models, which overexpress
the amyloid precursor protein (APP) to simulate AD
pathology, have reported decreased angiogenesis in the
presence of amyloid β peptides [22]. While a study using
the Tg2576 mouse model found increased microvessel
density and extensive disruption to tight junctions,
leading to a new hypothesis of amyloidogenesis [23].
Additionally, a corrosion cast model of vasculature in an
AD mouse model has suggested an increase in density,
as well as degeneration, of vessels [24]. Conversely, other
studies, in an aged APP/PS1 mouse model, have shown no
change in microvessel density [25].
To clarify these issues, we examined post mortem tissue
taken from the hippocampal formation to assess whether
microvascular morphology, specifically length density
(Lv) and diameter, was affected in different dementias,
placing particular emphasis on PSD. The CA1 subfield
was assessed due to its importance in relation to the
onset of dementia and specific susceptibility to both
increased AD-like pathology, risk of ischaemia and
hypoperfusion [26]. Lv measurements were conducted
using a spherical probe [27] and the diameter of cerebral
microvessels were assessed using software that had been
developed to measure vessel diameter and perivascular
space [28]. It is hypothesized that PSD cases will exhibit
reduced microvascular density and diameter, compared
with post-stroke nondemented (PSND). Preliminary
analysis from this study was presented in abstract form at
the 112th British Neuropathological Society Meeting,
January 2011 [29].
Materials and methods
Subjects and clinical features
Post mortem brain tissue was obtained from PSD and PSND
subjects [30]. AD and vascular dementia (VaD) subjects
and similar age controls were included for comparison.
The demographic details of the different subjects are pre-
sented in Table 1. The post-stroke subjects were enrolled in
the prospective Cognitive Function After Stroke (CogFAST)
study [30, 31]. Stroke patients aged ≥75 years were
selected on the basis that they were not demented 3
months after stroke and did not exhibit disabilities that
would prevent them from completing cognitive testing.
They received annual clinical assessments and a
neuropsychological test battery from baseline, including
the Cognitive Drug Research (CDR) battery, the Mini-
Mental State Exam (MMSE) and the Cambridge Assess-
ment of Mental Disorders in the Elderly (CAMCOG),
which generated subscores for various cognitive domains,
including memory and executive function [30, 32].
Subjects were classified as demented if they met DSM-
IIIR criteria for dementia. Controls aged >75 years were
only selected if they had not been diagnosed clinically
with cognitive impairment. There was no significant dif-
ference between the groups in average survival time (59.4
months) post-ischaemic injury event. Ethical approval
was granted by local research ethics committees for this
study (Newcastle upon Tyne Hospitals Trust, UK) and per-
mission for post mortem research using brain tissue was
granted for this project. All tissue was obtained from the
Newcastle Brain Tissue Resource.
Neuropathological examination
Final classification of demented subjects was assigned
based on established neuropathological diagnostic criteria
[33]. Briefly, haematoxylin-eosin staining was used for
assessment of structural integrity and infarcts, Nissl and
luxol fast blue staining for cellular pattern and myelin
loss, Bielschowsky’s silver impregnation for CERAD rating
of neuritic plaques, and tau immunohistochemistry for
Braak staging of neurofibrillary tangles. A diagnosis of
VaD was made when there were multiple or cystic
infarcts, lacunae, microinfarcts and small vessel disease,
and Braak stage <III [33]. A diagnosis of AD was con-
firmed on evidence of significant Alzheimer’s type pathol-
ogy, namely a Braak stage V–VI score, a moderate–severe
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CERAD score and an absence of significant vascular
pathology. Thal staging [34] was also performed: the
hippocampal formation and medial temporal lobe were
stained for amyloid (4G8 antibody) and each case was
graded, dependent on staging criteria. Vascular pathology
scores were derived from the presence of vascular lesions
in brain areas, including the frontal lobe at the level of the
olfactory bulbs, temporal lobe at level of the anterior
hippocampus, and basal ganglia at level of mamillary
body. Lesions including arteriolosclerosis, cerebral amy-
loid angiopathy, perivascular haemosiderin leakage,
perivascular space dilatation in the deep and juxtacortical
white matter (WM), myelin loss, and cortical micro
(<0.5 cm) and large (>0.5 cm) infarcts were recorded
with increasing severity resulting in greater scores [10].
Control subject tissue was determined not to have had
sufficient pathology to reach threshold to ascertain a
diagnosis for dementia (all pathological scores are shown
in Table 1)
Immunohistochemistry
Paraffin wax-embedded human hippocampal blocks were
selected based upon their proximity to a specific plane,
adjacent to the anterior pole of the lateral geniculate body
in the coronal plane, within the posterior section of the
hippocampus. Due to limited access to tissue, as a result of
working in the confines of a brain bank environment, only
oneblockper casewas available for analysis. For stereological
analysis, 15 30-μm-thick serial sections were cut from the
front of the block and mounted onto Superfrost+ slides
(Fisher Scientific, Loughborough, UK). Every fifth section
was then chosen so that three sections per case were
selected for uniform random sampling prior to staining
with each of the markers for immunohistochemistry:
glucose transporter 1 (GLUT1), collagen IV (COL4) and
smooth muscle α-actin (SMA).Ten-μm-thick sections were
used for vessel diameter analysis and mounted on 2%
3-aminopropyltriethoxysilane (APES) slides before being
stained using a standard immunohistochemical technique
for COL4.
In the initial preliminary study, serially cut 10-μm-thick
hippocampal sections taken from all dementia groups and
controls (Table 1) were used to perform standard two-
dimensional analysis of the microvasculature and labelled
with the same endothelial and basement membrane
markers.
Antigen heat retrieval was conducted by placing the
30-μm-thick sections in boiling 0.1 M citrate buffer for
10–15 min. The primary antibodies used were as follows:
GLUT1 (ThermoScientific, Loughborough, UK, 1:200),
COL4 (Sigma Aldrich, London, UK, 1:500) and SMA
Table 1. Demographic details and dementia type in the subjects
Controls PSND PSD VaD AD
Total number of controls or cases analysed 13 23 13 15 14
Age, years
Mean (range)
80.4 (72–94) 84.3 (78–94) 86.3 (80–96) 85.1 (71–97) 83.5 (70–91)
PMD, h
Mean (± 2SEM)
28.0 (6.1) 45 (11.2) 47.2 (14.6) 35.0 (13.4) 59 (15.8)
MMSE score mean (range) N/A 27.1 (24–30) 17.3 (12–24) N/A N/A
CAMCOG score (range) N/A 89.1 (82–99) 62.6 (24–80) N/A N/A
Braak stage
Mean (range)
2.4 (1–4) 2.5 (1–5) 2.6 (0–4) 2.0 (1–4) 5.3 (4–6)
CERAD
Mean (range)
0.5 (0–1) 1.4 (0–2) 1.0 (0–3) 1.0 (0–2) 3.0 (3–3)
2.2 (0–4) 2.8 (1–4) 1.6 (0–4) 1.9 (0–3) 3.7 (3–4)
Vascular pathology* (range) NPD 12.6 (7–16) 11.9 (8–17) 13 (12–14) N/A
Mean time from diagnosis of dementia to death (years) – – 2.38 4.58 4.0
*Vascular pathology scores were derived as described previously [10]. For stereological analysis, six samples representing each disease type or
controls were selected from the total pool and matched for age, post mortem interval (PMD) and fixation length.
The causes of death included bronchopneumonia, cardiac arrest and carcinoma with no particular distribution in any group. The time period
(weeks) of tissue fixation was in range 8–15 weeks for all the cases.
Abbreviations: AD, Alzheimer’s disease; CAMCOG, Cambridge Assessment of Mental Disorders in the Elderly; CERAD Consortium to Establish
a Registry for Alzheimer’s disease; MMSE, Mini-Mental State Exam; NPD, no neuropathological diagnosis; N/A, not applicable; PMD, post mortem
delay; PSND, post-stroke nondemented; PSD, post-stroke dementia; VaD, vascular dementia.
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(Sigma Aldrich, UK, 1:1000). A protease antigen retrieval
step was performed in the 10-μm-thick sections imm-
unostained for COL4 by treating with 0.6% subtilisin A,
type VIII bacterial protease (Sigma, London, UK) solution
for 10 min at room temperature. Appropriate secondary
antibodies were used, followed by incubation with
Vectastain Avidin/Biotinylated Complex (ABC) to increase
sensitivity of staining (Vector Labs, Peterborough, UK).
GLUT1, SMA and COL4 (10 μm) were visualized using
3,3′-diaminobenzidine and COL4 (30 μm) with Vector SG
and counterstained with haematoxylin (Figure 1).
Stereological and image analysis: length density
and vessel diameter
Initially, standard two-dimensional analysis was under-
taken to assess trends in microvascular changes within
various dementia groups [35]. However, to strengthen the
preliminary findings and discern the three-dimensional
aspect of the microvasculature, an adapted stereological
protocol was used.
The operators (M.J.C.B., hippocampus and L.N., EC) per-
formed analysis blindly in order to restrict operator bias.
A
C D
B
Figure 1. Microvasculature in the CA1 region of the hippocampal formation. (A) Microvessels immunostained with GLUT1 antibodies for
endothelial cells. (B) Microvessels and arterioles stained for basement membranes for COL4 (grey, arrowhead) and smooth muscle α-actin
(brown, open arrows). Note, GLUT1 stained microvessels appear discontinuous compared with COL4 (cf. A vs. B). (C and D) Morphometric
technique used to measure vasculature diameter stained with COL4 in 10 μm sections. (C) A longitudinal cut vessel and (D) a
transectionally cut vessel. Magnification bars: B = 100 μm; C and D = 10 μm.
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Using the Stereologer2000 software (Stereologer, Alexan-
dria, VA, USA), a spherical probe ‘space ball’ option was
selected to measure Lv of microvasculature [27]. The oper-
ating system was connected to a Zeiss Axiolab microscope
with a motorized stage (Prior Scientific, Cambridge, UK).
In this study, a spherical probe with a diameter of
18 μm was selected to allow for section shrinkage and an
appropriate guard volume. An outline was drawn denot-
ing the area of interest, which corresponded to the rel-
evant hippocampal subfield or cortical region at low
magnification (×5). Neuronal subfields were visualized
with the aid of haematoxylin counter staining. A digitally
generated, equally spaced grid was overlaid and used to
ensure random sampling within x- and y-axis of the ref-
erence area. A pilot study was performed to determine the
number of frames required to reduce the sampling coeffi-
cient of error (CE) to a satisfactory level. Such calculations
were based on the density of vessels in a particular region,
with the probe size and distance between probes altered
accordingly. Lv was calculated by counting the number of
intersections between the probe and the parameter – in
this instance microvasculature (ΣQ), and the area of sam-
pling probe (ΣA) [Lv = 2(ΣQ/ΣA)] at ×100 magnification
[27]. The number of intersections was used to estimate
the Lv for each case. As stated earlier, a lack of tissue avail-
ability prevented the full sampling of the region of inter-
est, thus precluding the measurement of volume of the
hippocampal structures and the subsequent calculation of
total length using Lv estimates.
Images for vessel diameter analysis were taken from
10-μm-thick sections stained with COL4 at × 40 magnifi-
cation using a Zeiss AX10 research-grade microscope
from the CA1 region. Approximately 30 images were
taken at random across the area of interest in each case.
Analysis of the vessel diameter was determined using soft-
ware developed to measure vessel diameter. The software
was calibrated by measuring a known length from a grati-
cule at the selected magnification of analysis [28]. Length
was calculated by using digital generated lines drawn by
the operator across the subject matter of interest. Each
vessel was measured three times and the average from
these measurements was recorded as the mean vessel
diameter (Figure 1B).
Statistical analysis
Statistical analysis was carried out using IBM SPSS
software (version 19.0). Significance was determined at
P ≤ 0.05. The Shapiro–Wilk test was used to test for nor-
mality of stereology data, parametric tests were used to
analyse hippocampal data, and nonparametric tests were
used for EC data. Group means were compared using an
anova and Tukey post-hoc test, or Kruskal–Wallis and
Mann–Whitney U-test. Correlations were assessed using
Pearson’s correlation. The Komolgrov–Smirnof test was
used to assess the normality of vessel diameter data,
as collective data were analysed from each group.
Nonparametric Kruskal–Wallis test was used to analyse
data and the Mann–Whitney U-test was used to establish
significance between groups. Cumulative frequency
analysis was performed of increasing vessel diameter to
determine if subpopulations of vessels were responsible
for changes in mean. Comparisons between group cumu-
lative frequencies and power analyses were carried out
using Multitab 16 Statistical Software (Minitab Inc., State
College, PA, USA).
Results
Neuropathological findings
There were no significant differences in any of the patho-
logical staging results between the PSND and PSD cases.
Significant increases (P ≤ 0.05) were apparent between
the AD group and other disease groups for Braak stages,
CERAD rating and Thal stages. The maximum Thal score
that could be assigned to an individual case was stage four,
due to the hippocampal formation and EC being the only
regions assessed (Table 1).
Length density assessment
Initial assessment of hippocampal microvasculature
was conducted using standard two-dimensional image
analysis with ImagePro 4.0 software (Mediacypernetics,
Silverspring, MD, USA). Ten-micrometre-thick sections
were stained with GLUT1 and the data were represented
as a percentage per area of staining in a total of 78
samples in all groups (Table 1). Significant increases
in percentage per area were found in GLUT1 density in
AD cases in the CA1, compared with PSND and PSD
(P = 0.011 and 0.037 respectively). A trend towards a sig-
nificant decrease in GLUT1 expression was found in PSND
cases, compared with controls (P = 0.073). A significant
increase was also found in COL4 percentage per area in
AD cases, compared with controls and VaD (P = 0.024
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and P = 0.05 respectively). The only significant difference
in CA2 was found with GLUT1, with an increase in AD
compared with VaD (P = 0.04). Based on these prelimi-
nary data, we wished to address issues surrounding
microvascular orientation, stemming from the use of
two-dimensional analysis, which may have led to inaccu-
rate conclusions. A modified stereological analysis was
thus performed to estimate the microvascular Lv
(Table 1).
The Lv results were normally distributed for all antibod-
ies used in both the CA1 and CA2 regions (P > 0.05).
GLUT1 Lv, was significantly increased in the CA1
(P ≤ 0.001, F = 23.28). Significant increases in mean Lv
in AD compared with all groups, except PSD (Figure 2A).
There was no significant difference in Lv in the CA2 region
(P = 0.459, F = 0.94).
COL4 Lv followed a similar pattern to GLUT1 changes,
predominantly labelling capillaries (Figure 1). In the CA1,
differences were apparent between groups (P ≤ 0.001,
F = 14.92). A significant increase in Lv was observed
between AD, compared with controls, PSND and VaD. Lv
was significantly increased in PSD cases, compared with
PSND and VaD. Similarly, in the CA2, as with GLUT1 Lv,
there were no significant differences in COL4 (P = 0.443,
F = 0.98).
As expected, SMA Lv was lower in all groups, compared
with other vascular markers, due to its specificity for
larger vessels (e.g. arterioles). Significant differences were
apparent between the groups in the CA1 (P = 0.004,
F = 5.22), where increases were observed in AD, com-
pared with controls (AD mean Lv = 0.118 mm/mm3 vs.
controls mean Lv = 0.058 mm/mm3, P = 0.027) and VaD
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Figure 2. Mean Lv values of GLUT1 and COL4 immunostained microvessels. Both markers (A and B) showed significant increases in Lv in
AD and PSD groups in CA1 region. Significance: **P ≤ 0.01 and ***P ≤ 0.001, different means against AD (grey), PSD (black) and both AD
and PSD (black bold). Results for CA2 region with no significant changes are not shown. (C) The correlation between Lv of GLUT1 and Lv of
COL4 immunostaining in CA1 showing internal consistency of measurement (r2 = 0.687, P = 0.000). Key: AD, Alzheimer’s disease;
controls, PSND, nondemented post-stroke subjects; PSD, post-stroke dementia; and VaD, vascular dementia.
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(mean Lv = 0.0475 mm/mm3, P = 0.004). No significant
difference was observed in CA2 (P = 0.959, F = 0.15).
SMA staining had a greater coefficient of error (CE) values
in all CA fields due to the relative low vessel density of
arterioles. We found no correlation between Lv and age of
subject, post mortem delay or length of tissue fixation.
The robustness of our Lv findings were verified by the
strong correlation between GLUT1 and COL4 in the CA1
(r2 = 0.687, P = 0.000). This indicated internal consist-
ency of the results obtained for individual microvascular
Lv (Figure 2C). Thus, changes in Lv in the CA1 and lack of
those in CA2 were reflected in both microvascular ele-
ments and profiles across all groups. The changes in either
marker were not correlated with any of the clinical or
psychometric measures including MMSE and CAMCOG
scores (data not shown).
We also performed analysis in the EC region within the
same tissue sections to ascertain microvascular density
changes in the neocortical region connected to the
hippocampal formation. Given the similarity in expression
between GLUT1 and COL4 found in the CA1, only GLUT1
Lv was analysed in the EC. We observed increases in AD
cases, compared with PSND (P = 0.004). Additionally,
PSD cases had significantly lower Lv than AD (P = 0.016).
PSND cases had significantly lower Lv, compared with
controls (P = 0.015).
Measurement of microvessel diameters
A total of 4082 microvessels were measured from all
groups collectively for vessel diameter analysis. However,
as there were differences in Lv between groups, the first 100
microvessels randomly selected in each case were analysed
and combined to calculate the mean vessel diameter for
each group (Figure 1). AD and VaD groups exhibited the
narrowest mean diameter (7.01 and 7.04 μm respec-
tively). The widest mean diameter was found in the PSND
(8.03 μm). However, controls and PSD had similar mean
diameters (7.47 and 7.44 μm respectively). After demon-
strating that the data were nonparametric, we observed a
significant difference between PSND and all other groups
(P = 0.000 for all groups). A significant difference was also
found between controls and PSD, compared with AD and
VaD (P = 0.000 in all cases, Figure 3A). The group results
were expressed in term of increasing diameter as cumula-
tive frequency (Figure 3B). Significant differences were
found between PSND compared with all other groups
except VaD using χ2 distribution analysis (Table 2).
Discussion
Recent advances have shown that cerebral microvascular
pathology is associated with age-related cognitive decline
[36–38]. Changes in microvessel morphology, including
thinning [17] and increased tortuosity [35, 39], have
been described in dementia. Our results augment previous
Figure 3. Microvessel diameters in PSD and AD vs. controls. (A) To
standardize comparisons between disorders, due to increased
microvessel densities in AD and PSD, the first 100 vessels measured
in each case were combined to calculate the mean vessel diameter
in each group. ***P ≤ 0.001. Bold black asterisks indicate
significance between PSND and all other groups. Black asterisks
indicate significant difference to PSD and grey asterisks show
difference to controls. Bars represent 2SEM. (B) Cumulative
frequency of increasing vessel diameter between groups. The
analysis allows to identify general trends in microvascular changes
within the population samples. Significant differences were found
between PSND against controls, VaD, AD and PSD subjects
(Table 2). Abbreviations and key to symbols: AD, Alzheimer’s
disease; PSND, nondemented post-stroke subjects; PSD, post-stroke
dementia; and VaD, vascular dementia.
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findings linking vascular pathology with cognitive decline
by showing increased microvascular density in the CA1
in PSD, compared with PSND, in both an endothelial
cell (GLUT1) and basement membrane (COL4) markers.
Such increases in Lv may be a reactive response, whereby
increases in the perfusion surface between blood and brain
result in remodelling of microvessels within a hypoxic
environment. This interpretation does not contradict the
notion that microvessel structural changes may reflect
increased tortuosity in PSD subjects. Our results thus
suggest that one factor that contributes to why some post-
stroke survivors succumb to dementia and others do not
relates to the observed sum total of the hippocampal
microvascular changes in PSD and PSND subjects. These
are likely acquired over a period of time from baseline 3
months after their stroke and found at death in those who
developed incident dementia compared with those who
did not.
We also demonstrated significant increases in Lv in AD
cases when compared against controls, PSND and VaD in
the CA1 region, and with PSND and PSD in the EC region.
This may relate to the presence of different components of
AD pathology (see Supplementary data and Table S1),
including amyloid plaques and neurofibrillary tangles
[40]. However, our findings are consistent with previous
studies showing an increase in Lv COL4 staining in the
CA1 [16], as well as the temporal cortex [15] of AD cases.
Our observations, which indicate no significant differ-
ences in the CA2 region, suggest that the increases in Lv
are regionally specific and can be attributed to increased
vulnerability caused by AD pathology, or as a result of
hypoperfusion, in the CA1 and EC. This appears to cor-
roborate previous findings [41], which have indicated a
selective reduction in capillary density within the CA1,
but not the CA3 region, albeit after acute ischaemic
insults.
Consistent with our previous work [42, 43], GLUT1
staining was not continuous along the vessel, unlike
COL4 (Figure 1). This implied that the numbers of inter-
sections recorded between the probe and the vessel may
not have fully corresponded with GLUT-1 expression. We
thus counteracted this issue by visualizing vessels with a
haematoxylin counterstain. Nevertheless, intersections
were only recorded when other portions of the vessel
were positively stained for GLUT1. The irregular
immunostaining of endothelial cells with GLUT1 along
the vessel is likely to be due to cellular damage [43]. It is
possible that the GLUT1-negative profiles, seen only with
haematoxylin counterstaining, reflect reduced GLUT1
protein in cases with dementia [44–46].
We assessed SMA immunoreactivity, which predomi-
nately labelled smooth muscle cells within perforating
branches of the hippocampal arterioles in CA1 and CA2.
A significant increase in SMA Lv was found in CA1 in AD
compared with controls and VaD; however, no difference
was found between PSND and PSD.
Previous neuroimaging studies have suggested that
medial temporal lobe atrophy occurs in AD [47], as well as
in PSD [48]. Thus, it could be argued that the observed
increase in Lv in AD and PSD is an indicator of hippocampal
atrophy or even tissue shrinkage, whereby loss of tissue
reduces the distance between existing microvascular pro-
files [35]. Valid comparisons can be made of post mortem
tissue as all the tissues were treated in a standardized
manner so any difference would be disease specific. In a
related study [10], we found that hippocampal neuronal
volume was decreased across all demented groups, thereby
suggesting that hippocampal atrophy is not a unique
finding to AD but is also apparent in PSD and VaD. Irrespec-
tive of such findings, the outcomes of the current study did
not concur with the notion that atrophy was the single
factor leading to an increase in Lv, as we found a significant
Table 2. Group differences between cumulative frequency distribution of vessel diameter
Controls PSND PSD VaD AD
Controls 49.11 (P ≤ 0.001) 3.51 (N/S) 63.56 (P ≤ 0.001) 0.535 (N/S)
PSND 49.11 (P ≤ 0.001) 23.74 (P ≤ 0.001) 1.49 (N/S) 55.24 (P ≤ 0.001)
PSD 3.51 (N/S) 23.74 (P ≤ 0.001) 34.90 (P ≤ 0.001) 6.12 (P = 0.013)
VaD 63.56 (P ≤ 0.001) 1.49 (N/S) 34.90 (P ≤ 0.001) 69.89 (P ≤ 0.001)
AD 0.535 (N/S) 55.24 (P ≤ 0.001) 6.12 (P = 0.013) 69.89 (P ≤ 0.001)
Chi2 (χ2) distribution values and significant differences between the cumulative frequencies of vessel diameter. Analysis was performed using
distribution analysis, with presumed distribution three parameter lognormal.
N/S denotes no significant difference.
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decrease in Lv in PSD cases in the EC compared with AD and
no change in Lv in the CA1. If one hypothesizes that
atrophy is the only factor leading to increased Lv then one
would expect similar findings in both regions. Additionally,
there was no change in Lv observed in VaD cases, compared
with control or PSND subjects. As atrophy could not be
measured in the cases included in this study (MRI scans
were not performed in all subjects who came to autopsy), it
cannot be ruled out as a confounding factor. However, if
the morphological changes were related to atrophy within
the whole hippocampal formation or medial temporal lobe
one would predict an increase in microvessel Lv, compared
with PSND subjects in all regions and including VaD
cases [49].
A technical limitation in this study was lack of avail-
ability of the whole reference volume (the hippocampus
and EC) for cutting and sampling. The tissue was obtained
from predefined blocks and as a result only one block per
case was available for sampling. As a result of these inher-
ent issues, we were unable to estimate volume of the
hippocampus, meaning it was not possible to convert Lv
into total length per structure (that is, the hippocampus).
As Lv is a measure that relies on the relationship between
the numerator (in this case, the number of vessel intersec-
tions) and the denominator (the background neuronal
tissue), this leaves open the possibility of ‘reference trap’
bias from tissue shrinkage as, if one assumes that the
density of a component within a structure acts as a proxy
for its total number, one must also make the assumption
that the reference volume of the structure itself must
remain unchanged across the groups measured.
Although we cannot rule out the effects of shrinkage, all
sections were processed identically and assessment of
section thickness revealed no significant differences
between groups making group effects unlikely. While only
six cases were analysed in each group, retrospective power
analysis showed that there is a significant number of cases
per group to obtain a high level of significant power.
Consistent with previous studies [14, 17], a significant
decrease in vessel diameter was identified in AD and VaD.
Possible string vessels [36, 43] were often observed but
not quantified. These results may explain the commonly
associated reduced CBF previously described in dementia
and GLUT1 protein density [35]. A number of studies
have suggested that amyloid β may play a direct role in
increasing vasoconstriction [50] or that nitric oxide, a
natural vasodilator, is altered in dementia [51]. Another
study has suggested that the vasoconstrictor endothelin-1
(ET-1) may play a role in both AD and VaD. However,
changes in the mRNA of the endothelin converting
enzyme (ECE-1) were small and increases found in ET-1
are most likely be caused by Aβ mediated up-regulation of
the converting enzymes [52, 53]. Furthermore, inhibiting
angiotensin II, a potent vasoconstrictor may improve cog-
nitive function in AD and VaD by ameliorating hypoten-
sion. However, angiotensin II is also involved in inhibiting
the release of acetylcholine and the up-regulation of
inflammatory response [54, 55]. Patients with AD are
less likely to have been prescribed angiotensin II receptor
blockers compared with age matched nondemented con-
trols [56], which may affect vessel diameter. Microvessel
diameter was significantly increased in PSND, compared
with controls and no significance difference was found
between PSD and controls. The results outlined may thus
suggest either that vessels in PSND are more vasoreactive
and responsive to their environment after stroke and
undergo re-modelling (unlike PSD cases), or, alternatively,
that the vessel diameter may not be related to cognitive
function after stroke.
Cumulative frequency analysis showed that there were
significant differences in distribution analysis of increas-
ing vessel diameter between the groups, suggesting varia-
tions in subpopulations of hippocampal microvessels. In
the PSND group, vessel diameters were significantly wider
than all the other groups. Cumulative frequency analysis
suggested that there were greater proportions of vessels
with a diameter (between approximately 7 and 12 μm),
compared with the other groups, and that the mean diam-
eter increase was not caused by analysing a larger number
of large vessels, including arterioles. This could mean that
the PSND group had microvasculature that is more adapt-
able in response to hypoperfusion. Distribution analysis
showed that there was a significant difference between
the PSND group and all other groups, except VaD. This
suggests a significant variation in the composition of
microvasculature across all groups.
In sum, our results show an increase in microvascular Lv
in PSD and AD and, furthermore, that microvessels were
significantly wider in PSND cases. Moreover, there were
differential microvascular changes across the regions of
the hippocampus, with significant differences only found
in the CA1 region. A significant increase was also observed
in AD cases compared with both PSND and PSD in the EC.
Given that there is an increase in Lv in PSD cases compared
with PSND, but that they exhibit similar but minimal
neurodegenerative pathology, the microvascular changes
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found may be marker for hypoperfusion in post-stroke sur-
vivors. While there were no significant differences in Lv
between PSND and VaD subjects, it is possible that the
microvasculature attributes are similar in PSD and AD in
the hippocampus (but not EC) but that different mecha-
nisms occur in VaD. A significant increase in mean vascu-
lar diameter (between 7 and 12 μm) was also found in
PSND cases, compared with other groups; however, there
was no significant increase in the proportion of larger
vessels, that is, arterioles. Furthermore, there was no sig-
nificant difference in vessel diameter between controls and
PSD suggesting that microvessels may not possess the
ability to adapt to their environment and thus remained
unaltered. It has been widely hypothesized that the
decrease in diameter in AD and VaD would reduce CBF and
increase brain hypoperfusion. This suggests that the
increases in the proportion of small narrower vessels in AD
and PSD, when compared with PSND, may be an indicator
of new microvascular loops via angiogenic processes [23],
or increased twisting of existing profiles [36]. However,
alternative factors, such as atrophy, cannot be completely
dismissed as a reason for the increases in microvascular
density found in AD and PSD.
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